Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis.

Autor:	Maretbayeva SM; Partners In Health, Almaty, Kazakhstan., Rakisheva AS; JSC 'National Medical University' named after Asfendiyarov, Kazakhstan., Adenov MM; National Scientific Center of Phthisiopulmonology of the Ministry of Health of the Republic of Kazakhstan, Kazakhstan., Yeraliyeva LT; National Scientific Center of Phthisiopulmonology of the Ministry of Health of the Republic of Kazakhstan, Kazakhstan., Algozhin YZ; Partners In Health, Almaty, Kazakhstan., Stambekova AT; Partners In Health, Almaty, Kazakhstan., Berikova EA; National Scientific Center of Phthisiopulmonology of the Ministry of Health of the Republic of Kazakhstan, Kazakhstan., Yedilbayev A; World Health Organization Regional Office for Europe, Kazakhstan., Rich ML; Partners In Health, Boston, USA; Harvard Medical School, Boston, USA., Seung KJ; Partners In Health, Boston, USA; Harvard Medical School, Boston, USA., Issayeva AM; JSC 'National Medical University' named after Asfendiyarov, Kazakhstan. Electronic address: issayeva17@mail.ru.
Jazyk:	angličtina
Zdroj:	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2021 Dec; Vol. 113 Suppl 1, pp. S91-S95. Date of Electronic Publication: 2021 Apr 03.
DOI:	10.1016/j.ijid.2021.03.075
Abstrakt:	Rifampicin-resistant/multidrug-resistant (RR/MDR) and extensively drug-resistant (XDR) strains of M. tuberculosis (TB) are serious public health problem in Kazakhstan. In 2012 and 2013, stringent regulatory authorities approved the first new TB drugs in fifty years, bedaquiline and delamanid, offering hope for more effective and less toxic MDR-TB treatment. The endTB Observational Study is a multi-country study that enrolled patients receiving a bedaquiline- or delamanid-containing regimen for RR/MDR-TB between 01 April 2015 and 30 September 2018. In Kazakhstan, 675 patients participated in the study; all had at least 6-months or longer of follow-up after the start of treatment. The present analysis focuses on endTB Observational Study patients living in Kazakhstan who had a positive baseline sputum culture (220 patients) and initiated a bedaquiline- or delamanid-containing regimen between February 1, 2016 and March 31, 2018. Of them, 195 (89%) of patients experienced culture conversion within six months. (Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu